Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1425133 | 0.85 | KEAP1 (0.36) | KEAP1TSHRHCRTR1HCRTR2HSP90AA1 | |
| SCHEMBL1424288 | 0.81 | HCRTR1 (0.39) | KEAP1TSHRHCRTR1HCRTR2HPGD | |
| SCHEMBL1424286 | 0.79 | ALDH1A1 (0.38) | KEAP1TSHRHCRTR1HCRTR2HPGD | |
| SCHEMBL14275294 | 0.78 | RIPK1 (0.30) | RIPK1 | |
| SCHEMBL8017533 | 0.74 | HTR2C (0.47) | RIPK1HTR2CSLC6A4 | |
| SCHEMBL14275285 | 0.73 | ALDH1A1 (0.35) | HCRTR1HCRTR2HPGDRIPK1HTR2C | |
| SCHEMBL22657965 | 0.72 | HTR2C (0.45) | TSHRRIPK1HTR2CSLC6A4 | |
| SCHEMBL28363287 | 0.72 | TSHR (0.46) | KEAP1TSHRHCRTR1HCRTR2MAPK1 | |
| SCHEMBL1403561 | 0.72 | HTR2C (0.40) | RIPK1HTR2CSLC6A4 | |
| SCHEMBL22657817 | 0.71 | SLC6A4 (0.44) | HSP90AA1RIPK1HTR2CSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140113935-A1 | N-METHYLAMINOMETHYL ISOINDOLE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2014-04-24 | — | — | US | disclosed |
| US-8648096-B2 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2014-02-11 | — | — | US | disclosed |
| US-8648096-B2 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2014-02-11 | — | — | US | disclosed |
| US-8648096-B2 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2076260-B1 | N-METHYLAMINOMETHYL ISOINDOLE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2076260-A1 | N-METHYLAMINOMETHYL ISOINDOLE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20080214615-A1 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2008-09-04 | — | — | US | disclosed |
| US-20080214615-A1 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2008-09-04 | — | — | US | disclosed |
| US-20080214615-A1 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2008-09-04 | — | — | US | disclosed |
| WO-2008033567-A1 | N-METHYLAMINOMETHYL ISOINDOLE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214615-A1 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | INMT, HNMT, TPMT | KEAP1 4137/4885TSHR 4665/4885HCRTR1 3441/4885 |
| US-20140113935-A1 | N-METHYLAMINOMETHYL ISOINDOLE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | INMT, HNMT, TPMT | KEAP1 4137/4885TSHR 4665/4885HCRTR1 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.